Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Rheumatology

Diagnosis, Testing, and Understanding Your Medical Reports

At a Glance

Antisynthetase Syndrome (ASyS) is diagnosed using a combination of clinical signs and specific autoantibody tests like the myositis panel. Confirming the diagnosis requires identifying a target antibody and assessing lung and muscle health through baseline HRCT scans and pulmonary function tests.

Diagnosing Antisynthetase Syndrome (ASyS) is like solving a high-stakes puzzle. Because the disease is rare and can hide behind other conditions, doctors rely on a combination of blood work, specialized imaging, and expert-defined criteria to confirm the diagnosis [1][2]. Understanding your reports allows you to ensure no piece of the puzzle is missing.

The Diagnostic Framework

Experts generally use two main sets of criteria (the Connors or Solomon criteria) to confirm ASyS. Both agree on a core requirement: you must have at least one antisynthetase autoantibody (like Jo-1, PL-7, or PL-12) plus one or more clinical signs, such as lung disease, muscle inflammation, or “mechanic’s hands” [2][3]. Newer 2024 guidelines (ENMC criteria) emphasize that Interstitial Lung Disease (ILD) and specific antibodies are the most critical factors for diagnosis [2][1].

Decoding Your Reports

Medical reports for ASyS are dense with technical terms. Here are the most common terms you will see:

1. Autoantibody Testing (The Blood Work)

The definitive test is a Myositis-Specific Antibody (MSA) Panel.

  • The Problem: Standard “line-blot” or “ELISA” tests at local labs are convenient but can sometimes miss rare antibodies like anti-OJ or anti-KS [4][5].
  • The Solution: If your symptoms strongly suggest ASyS but your panel is negative, specialists may order RNA Immunoprecipitation (RIP). This is the “gold standard” test that is more sensitive and accurate for identifying rare subtypes [6][7].

2. High-Resolution CT (The Lung Image)

An HRCT is a specialized chest scan that provides a detailed “map” of your lungs [8]. Common patterns in ASyS include:

  • NSIP (Non-Specific Interstitial Pneumonia): A common pattern often showing a “ground-glass” appearance [9][10].
  • OP (Organizing Pneumonia): Areas of inflammation that look like “patches” or “consolidation” [11][12].
  • Ground-Glass Opacities (GGO): A term for hazy areas on the scan that represent active inflammation [13][14].

3. Muscle Assessment

While many patients have high CK (creatine kinase) levels, some have “amyopathic” disease—where the lungs are affected but the muscles appear normal on standard blood tests [15][9]. In these cases, doctors may use an MRI or a PET/CT scan to find hidden muscle inflammation [16][17].

Your Completeness Checklist

To ensure your diagnosis is robust, verify that your medical file contains the following “baseline” data points:

  • [ ] Full Myositis Panel: Confirms the specific antibody (e.g., Jo-1 vs. non-Jo-1) [18][19].
  • [ ] Baseline HRCT: Provides the initial “map” of lung health [8][20].
  • [ ] Pulmonary Function Tests (PFTs): Measures how much air your lungs can hold (FVC) and how well they move oxygen into your blood (DLCO) [21][22].
  • [ ] Echocardiogram: A heart ultrasound to check for Pulmonary Hypertension (high blood pressure in the lung vessels) [23][24].
  • [ ] CK/Aldolase Levels: Baseline blood markers for muscle inflammation. Aldolase is another muscle enzyme similar to CK, which can sometimes be elevated even when CK is normal [15][25].
  • [ ] Nailfold Capillaroscopy: A simple microscopic look at the blood vessels in your cuticles to check for microvascular damage [23].

If any of these are missing, it is a good starting point for a conversation with your specialist to ensure your care plan is fully informed [26][27].

Common questions in this guide

What if my myositis antibody panel is negative but I have ASyS symptoms?
Standard antibody tests can sometimes miss rare antibodies associated with Antisynthetase Syndrome. If your symptoms strongly suggest the condition, your specialist may order an RNA Immunoprecipitation (RIP) test, which is a highly sensitive test for identifying rare subtypes like anti-OJ or anti-KS.
What do terms like 'ground-glass' or 'NSIP' mean on my HRCT lung scan?
'Ground-glass' is a radiology term for hazy areas on your lung scan that typically indicate active inflammation. NSIP (Non-Specific Interstitial Pneumonia) is a common inflammatory lung pattern seen in Antisynthetase Syndrome that often presents with this ground-glass appearance.
Can I have Antisynthetase Syndrome if my muscle enzyme (CK) levels are normal?
Yes, some patients have an 'amyopathic' form of the disease where the lungs are affected but standard muscle blood tests like CK are normal. In these cases, doctors may use an MRI or a PET/CT scan to find hidden muscle inflammation.
What baseline tests do I need when diagnosed with Antisynthetase Syndrome?
A complete baseline evaluation should include a full myositis antibody panel, a high-resolution CT (HRCT) scan of your lungs, and pulmonary function tests (PFTs). Your doctor will also likely order an echocardiogram to check your heart and blood tests for muscle enzymes like CK and aldolase.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.My antibody panel was negative, but I have several classic symptoms—could we perform an 'RNA Immunoprecipitation' test to look for rare antibodies like anti-OJ or anti-KS?
  2. 2.Looking at my HRCT report, does my lung pattern suggest 'NSIP' or 'OP,' and what does that mean for my initial treatment response?
  3. 3.My muscle enzymes (CK) are normal, but I feel weak. Should we consider an MRI of my muscles or a PET/CT to check for 'amyopathic' (subclinical) inflammation?
  4. 4.Which specific diagnostic criteria (Connors, Solomon, or the new ENMC criteria) are you using to define my case?
  5. 5.Can we review my baseline 'PFTs' (Pulmonary Function Tests) and 'Echocardiogram' together to ensure we have a complete starting point?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (27)
  1. 1

    273rd ENMC International workshop: Clinico-Sero-morphological classification of the Antisynthetase syndrome. Amsterdam, The Netherlands, 27-29 October 2023.

    Stenzel W, Mammen AL, Gallay L, et al.

    Neuromuscular disorders : NMD 2024; (45()):104453 doi:10.1016/j.nmd.2024.104453.

    PMID: 39490006
  2. 2

    Anti-synthetase syndrome: A focus on interstitial lung disease as a diagnostic criteria.

    Peterson JA, Cook C, Gao H, et al.

    Respiratory medicine and research 2025; (88()):101190 doi:10.1016/j.resmer.2025.101190.

    PMID: 40706528
  3. 3

    Antisynthetase syndrome - much more than just a myopathy.

    Opinc AH, Makowska JS

    Seminars in arthritis and rheumatism 2021; (51(1)):72-83 doi:10.1016/j.semarthrit.2020.09.020.

    PMID: 33360231
  4. 4

    The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.

    Tansley SL, Li D, Betteridge ZE, McHugh NJ

    Rheumatology (Oxford, England) 2020; (59(8)):2109-2114 doi:10.1093/rheumatology/keaa021.

    PMID: 32030410
  5. 5

    Newer Autoantibodies and Laboratory Assessments in Myositis.

    Harvey GR, MacFadyen C, Tansley SL

    Current rheumatology reports 2024; (27(1)):5 doi:10.1007/s11926-024-01171-8.

    PMID: 39636383
  6. 6

    The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population.

    Loganathan A, McMorrow F, Lu H, et al.

    Frontiers in immunology 2022; (13()):975939 doi:10.3389/fimmu.2022.975939.

    PMID: 36177007
  7. 7

    Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard: A systematic review and meta-analysis.

    Gono T, Gil-Vila A, Selva-O'Callaghan A, et al.

    Seminars in arthritis and rheumatism 2025; (75()):152858 doi:10.1016/j.semarthrit.2025.152858.

    PMID: 41176843
  8. 8

    Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies.

    Laporte A, Mariampillai K, Allenbach Y, et al.

    European radiology 2022; (32(5)):3480-3489 doi:10.1007/s00330-021-08411-w.

    PMID: 35022809
  9. 9

    Single Nucleotide Polymorphism in the IL17A Gene Is Associated with Interstitial Lung Disease Positive to Anti-Jo1 Antisynthetase Autoantibodies.

    Ponce-Gallegos MA, González-Pérez MI, Mejía M, et al.

    Life (Basel, Switzerland) 2021; (11(2)) doi:10.3390/life11020174.

    PMID: 33672430
  10. 10

    A Rare Case of Anti-glycyl transfer RNA (tRNA) Synthetase Antibody-Related Non-specific Interstitial Pneumonia.

    Khatri Chhetri RC, Gole S, Mallari AJP, et al.

    Cureus 2022; (14(6)):e26159 doi:10.7759/cureus.26159.

    PMID: 35832751
  11. 11

    High-resolution computed tomography (HRCT) analysis in anti-synthase antibody syndrome with organizing pneumonia.

    Li X, Wu Q, Peng S, et al.

    Medicina clinica 2022; (159(2)):59-64 doi:10.1016/j.medcli.2021.08.003.

    PMID: 34702560
  12. 12

    Jo1-antisynthetase syndrome and severe interstitial lung disease with organising pneumonia on histopathology with favourable outcome on early combined treatment with corticosteroids, mycophenolate mofetil and rituximab.

    Rüegg CA, Maurer B, Laube I, Scholtze D

    BMJ case reports 2019; (12(9)) doi:10.1136/bcr-2019-231006.

    PMID: 31519721
  13. 13

    Longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease on high-resolution computed tomography, a prospective cohort study.

    Qiang Y, Wang H, Ni Y, et al.

    BMC pulmonary medicine 2025; (25(1)):503 doi:10.1186/s12890-025-03962-w.

    PMID: 41184994
  14. 14

    Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome.

    Liu H, Xie S, Liang T, et al.

    European radiology 2019; (29(10)):5349-5357 doi:10.1007/s00330-019-06152-5.

    PMID: 30919069
  15. 15

    Presenting clinical and imaging features of patients with clinically amyopathic interstitial lung disease associated with myositis-specific autoantibodies.

    Tzilas V, Tzouvelekis A, Sotiropoulou V, et al.

    Frontiers in medicine 2024; (11()):1392659 doi:10.3389/fmed.2024.1392659.

    PMID: 38711778
  16. 16

    F18-FDG PET/CT in a patient with Antisynthetase Syndrome.

    Nazerani-Zemann T, Stanzel S, Gstettner C, et al.

    Nuklearmedizin. Nuclear medicine 2023; (62(2)):73-74 doi:10.1055/a-1996-0157.

    PMID: 36599440
  17. 17

    Antisynthetase Syndrome With Classic Features and Anti‑PL‑7 Positivity: A Rare Immunologic Variant.

    Arrazola-Mendoza KS, González-Chávez HE, De la Peña-Camacho F, et al.

    Cureus 2025; (17(9)):e93503 doi:10.7759/cureus.93503.

    PMID: 41170284
  18. 18

    Clinical heterogeneity and prognostic factors of anti-synthetase syndrome: a multi-centred retrospective cohort study.

    Tang HS, Tang IYK, Ho RTC, et al.

    Rheumatology (Oxford, England) 2025; (64(1)):212-220 doi:10.1093/rheumatology/kead671.

    PMID: 38096583
  19. 19

    Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services.

    Barratt SL, Adamali HH, Cotton C, et al.

    BMJ open respiratory research 2021; (8(1)) doi:10.1136/bmjresp-2020-000829.

    PMID: 33419741
  20. 20

    A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease.

    Patel P, Marinock JM, Ajmeri A, Brent LH

    International journal of molecular sciences 2024; (25(8)) doi:10.3390/ijms25084453.

    PMID: 38674039
  21. 21

    Pulmonary Involvement in the Antisynthetase Syndrome: A Comparative Cross-sectional Study.

    Andersson H, Aaløkken TM, Günther A, et al.

    The Journal of rheumatology 2016; (43(6)):1107-13 doi:10.3899/jrheum.151067.

    PMID: 27036381
  22. 22

    Antisynthetase Syndrome-Associated Interstitial Lung Disease: Monitoring of Immunosuppressive Treatment Effects by Chest Computed Tomography.

    Korsten P, Rademacher JG, Riedel L, et al.

    Frontiers in medicine 2020; (7()):609595 doi:10.3389/fmed.2020.609595.

    PMID: 33569387
  23. 23

    Distinct Nailfold Videocapillaroscopy Findings in Patients With Anti-Aminoacyl-tRNA Synthetase Antibodies.

    Mugii N, Hamaguchi Y, Fushida N, et al.

    The Journal of dermatology 2026; (53(2)):318-322 doi:10.1111/1346-8138.70081.

    PMID: 41312673
  24. 24

    Echocardiographic characteristics of patients with antisynthetase syndrome.

    Bryan JL, Matar R, Raviprasad A, et al.

    Pulmonary circulation 2022; (12(2)):e12084 doi:10.1002/pul2.12084.

    PMID: 35514779
  25. 25

    Poor prognostic factors for relapse of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies after combination therapy.

    Matsuda S, Kotani T, Oe K, et al.

    Frontiers in immunology 2024; (15()):1407633 doi:10.3389/fimmu.2024.1407633.

    PMID: 39346900
  26. 26

    A multidisciplinary approach to the diagnosis of antisynthetase syndrome.

    Wells M, Alawi S, Thin KYM, et al.

    Frontiers in medicine 2022; (9()):959653 doi:10.3389/fmed.2022.959653.

    PMID: 36186825
  27. 27

    Antisynthetase syndrome and pulmonary hypertension: report of two cases and review of the literature.

    García-Fernández A, Quezada-Loaiza CA, de la Puente-Bujidos C

    Modern rheumatology case reports 2021; (5(1)):152-155 doi:10.1080/24725625.2020.1794521.

    PMID: 32697139

This page explains Antisynthetase Syndrome testing and diagnostic terminology for educational purposes. Your rheumatologist and pulmonologist are the best sources for interpreting your specific medical reports.

Get notified when new evidence is published on Antisynthetase syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.